Isoniazid-resistant tuberculosis: A problem we can no longer ignore
Autoři:
Giorgia Sulis aff001; Madhukar Pai aff001
Působiště autorů:
Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, Quebec, Canada
aff001; McGill International TB Centre, McGill University, Montreal, Quebec, Canada
aff002; Manipal McGill Program for Infectious Diseases, Manipal Centre for Infectious Diseases, Manipal Academy of Higher Education, Manipal, Karnataka, India
aff003
Vyšlo v časopise:
Isoniazid-resistant tuberculosis: A problem we can no longer ignore. PLoS Med 17(1): e32767. doi:10.1371/journal.pmed.1003023
Kategorie:
Perspective
doi:
https://doi.org/10.1371/journal.pmed.1003023
Souhrn
Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis,
Klíčová slova:
Drug research and development – Drug screening – Europe – Extensively drug-resistant tuberculosis – Isoniazid – Mutation detection – Tuberculosis – Tuberculosis diagnosis and management
Zdroje
1. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update. Geneva: World Health Organization (WHO); 2013.
2. Kendall EA, Sahu S, Pai M, Fox GJ, Varaine F, Cox H, et al. What will it take to eliminate drug-resistant tuberculosis? Int J Tuberc Lung Dis. 2019;23(5):535–46. Epub 2019/05/18. doi: 10.5588/ijtld.18.0217 31097060; PubMed Central PMCID: PMC6600801.
3. Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, et al. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data. PLoS Med. 2020;17(1): e1003008. https://doi.org/10.1371/journal.pmed.1003008.
4. Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(2):223–34. doi: 10.1016/S1473-3099(16)30407-8 27865891.
5. WHO treatment guidelines for isoniazid-resistant tuberculosis: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis. Geneva: World Health Organization (WHO); 2018.
6. Fregonese F, Ahuja SD, Akkerman OW, Arakaki-Sanchez D, Ayakaka I, Baghaei P, et al. Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2018;6(4):265–75. doi: 10.1016/S2213-2600(18)30078-X 29595509.
7. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med. 2019;200(10):e93–e142. doi: 10.1164/rccm.201909-1874ST 31729908.
8. Talbot EA, Pai M. Tackling drug-resistant tuberculosis: we need a critical synergy of product and process innovations. Int J Tuberc Lung Dis. 2019;23(7):774–82. doi: 10.5588/ijtld.18.0715 31439108.
9. Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, et al. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project. Lancet Infect Dis. 2016;16(10):1185–92. doi: 10.1016/S1473-3099(16)30190-6 27397590; PubMed Central PMCID: PMC5030278.
10. Chakravorty S, Roh SS, Glass J, Smith LE, Simmons AM, Lund K, et al. Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use. J Clin Microbiol. 2017;55(1):183–98. doi: 10.1128/JCM.01771-16 27807153; PubMed Central PMCID: PMC5228229.
11. Global tuberculosis report 2019. Geneva: World Health Organization (WHO); 2019.
12. Pipeline Report 2019. Tuberculosis diagnostics. New York: Treatment Action Group (TAG); 2019.
13. Temesgen Z, Cirillo DM, Raviglione MC. Precision medicine and public health interventions: tuberculosis as a model? Lancet Public Health. 2019;4(8):e374. doi: 10.1016/S2468-2667(19)30130-6 31376856.
14. Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, et al. Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues. Nat Rev Microbiol. 2019;17(9):533–45. doi: 10.1038/s41579-019-0214-5 31209399.
15. Unitaid’s investment in tuberculosis hits record levels with new grant for diagnostic technologies [media release]. Unitaid [Internet]. 2019 Jul 4 [cited 2019 November 17]. Available from: https://unitaid.org/news-blog/unitaids-investment-in-tuberculosis-hits-record-levels-with-new-grant-for-diagnostic-technologies/#en
Článek vyšel v časopise
PLOS Medicine
2020 Číslo 1
- Vidoucí nevidoucí, Alzheimer v krvi, obézní gen a emocionální vzpomínky – „jednohubky“ z výzkumu 35/2025
- Vakcinace proti hepatitidě A se nejvíc zanedbala u osob s onemocněním jater
- Jak sebepoškozování dospívajících souvisí se závislostí?
- Ukažte mi, jak kašlete, a já vám řeknu, co vám je
- AI hledá nová antibiotika ve zvířecích jedech
Nejčtenější v tomto čísle
- Association of puberty timing with type 2 diabetes: A systematic review and meta-analysis
- Advances in cervical cancer prevention: Efficacy, effectiveness, elimination?
- Effectiveness of a scalable group-based education and monitoring program, delivered by health workers, to improve control of hypertension in rural India: A cluster randomised controlled trial
- Infectious disease pandemic planning and response: Incorporating decision analysis